Merlin Biosciences
Jump to navigation
Jump to search
A venture-capital firm founded in 1996 by biotech entrepeneur Christopher Evans, Merlin Biosciences is one of the largest investors in the European bioscience market and has raised more than €500 million in syndicated equity finance for its portfolio companies.
Many of the companies in which Merlin has invested have been struggling in a harsh environment for small biotech firms.
Its portfolio interests include theraputic cancer pharmaceuticals, viral vector vaccine delivery, and broad-spectrum antibiotics.
Personnel
- Christopher Evans, Chariman and founder
- Mark Clement, Chief Executive
